LAVA Therapeutics Files 8-K
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, 8-K, company-update
TL;DR
LAVA Therapeutics filed an 8-K on Oct 2, 2025, updating corporate info.
AI Summary
LAVA Therapeutics N.V. filed an 8-K on October 2, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at Yalelaan 62, Utrecht, The Netherlands, and its telephone number. It also notes the company's former name, LAVA Therapeutics BV, which changed on January 15, 2021.
Why It Matters
This filing provides an update on LAVA Therapeutics' corporate structure and reporting, which is important for investors tracking the company's official disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- October 2, 2025 (date) — Date of Report
- Yalelaan 62, Utrecht, The Netherlands (location) — Principal executive offices
- LAVA Therapeutics BV (company) — Former company name
- January 15, 2021 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for LAVA Therapeutics N.V.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 2, 2025.
Where are LAVA Therapeutics N.V.'s principal executive offices located?
LAVA Therapeutics N.V.'s principal executive offices are located at Yalelaan 62, Utrecht, The Netherlands.
What was LAVA Therapeutics N.V.'s former name?
LAVA Therapeutics N.V.'s former name was LAVA Therapeutics BV.
When did LAVA Therapeutics N.V. change its name from LAVA Therapeutics BV?
The date of the name change from LAVA Therapeutics BV to LAVA Therapeutics N.V. was January 15, 2021.
What is the SEC file number for LAVA Therapeutics N.V.?
The SEC file number for LAVA Therapeutics N.V. is 001-40241.
Filing Stats: 1,677 words · 7 min read · ~6 pages · Grade level 15.7 · Accepted 2025-10-02 17:03:03
Filing Documents
- tm2527813d2_8k.htm (8-K) — 34KB
- tm2527813d2_ex99-1.htm (EX-99.1) — 23KB
- tm2527813d2_ex99-1img001.jpg (GRAPHIC) — 29KB
- tm2527813d2_ex99-1img002.jpg (GRAPHIC) — 26KB
- 0001104659-25-096152.txt ( ) — 307KB
- lvtx-20251002.xsd (EX-101.SCH) — 3KB
- lvtx-20251002_lab.xml (EX-101.LAB) — 33KB
- lvtx-20251002_pre.xml (EX-101.PRE) — 22KB
- tm2527813d2_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 2, LAVA Therapeutics N.V. (the " Company ") and XOMA Royalty Corporation (" Buyer ") issued a joint press release announcing the extension of the expiration of the tender offer to purchase all issued and outstanding common shares, nominal value 0.12 per share, of the Company (the " Shares "), for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right (" CVR ") for each Share representing the right to receive 75% of the net proceeds related to the Company's two partnered assets and 75% of any net proceeds from any out license or sale of the Company's unpartnered programs (the " Offer "). The Offer was previously scheduled to expire one minute after 11:59 p.m., New York City time, on October 3, 2025, in accordance with that certain share purchase agreement, dated as of August 3, 2025 (the " Purchase Agreement "). The expiration date of the Offer is extended to expire one minute after 11:59 p.m., New York City time, on October 17, 2025, unless it is extended further or earlier terminated in accordance with the Purchase Agreement. Additional Information and Where to Find It In connection with the proposed transactions between the Company and Buyer, Buyer filed a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission (the "SEC") and the Company filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC related to the tender offer. The Company also filed a proxy statement in connection with the originally scheduled extraordinary general meeting ("EGM") at which the Company shareholders were requested to vote on certain proposed resolutions (the "EGM Proposals") in connection with the transactions. The Company plans to file a revised proxy statement with the SEC and send a revised proxy statement and proxy card to each shareholder entitled to vote at the reconvened extraordinary general meeting. INVESTORS AND S
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Joint Press Release dated October 2, 2025. 104 Cover page interactive data file (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LAVA Therapeutics N.V. Date: October 2, 2025 By: /s/ Fred Powell Fred Powell Chief Financial Officer